Predictive proteins

Biomarkers in COVID-19 patients could predict how ill they become

Researchers at the Francis Crick Institute and Charité – Universitätsmedizin Berlin have identified 27 protein biomarkers that could be used to predict whether a patient with COVID-19 is likely to become severely ill with the disease.

People infected with SARS-CoV-2, the virus which causes COVID-19, respond differently. Some do not develop any symptoms, some need to be hospitalised and, for some, the disease is fatal. In this study, published in Cell Systems, researchers found 27 potential biomarkers that are present in different levels in patients with COVID-19, depending on the severity of their symptoms. The markers could help doctors to predict how ill a patient will become and provide scientists with new targets for drug development.

Photo
Graphical abstract

Image source: Messner et al., Cell Systems 2020 (CC BY 4.0)

The researchers refined an analysis method called mass spectrometry to rapidly test for the presence and quantity of various proteins in the blood plasma. This platform was developed at the Francis Crick Institute and applied to analyse serum of 31 COVID-19 patients at the Berlin University hospital Charité. Their results were further validated in 17 patients with COVID-19 at the same hospital and in 15 healthy people. The researchers hope their findings will lead to the development of simple routine tests to check for the levels for one or some of these proteins in patients with COVID-19. The results of such tests could be used to support doctors in deciding what treatment to give.

Christoph Messner, one of the lead authors and postdoc in the Molecular Biology of Metabolism Laboratory at the Crick, says: “A test to help doctors predict whether a COVID-19 patient is likely to become critical or not would be invaluable. It will help them make decisions about how to best manage the disease for each patient as well as identify those most at risk. We hope the biomarkers we’ve identified will lead to the development of these vitally needed tests.”

While our technology platform was not developed specifically for COVID-19, it has proven highly useful to gain novel insights into this disease

Vadim Demichev

Three of the key proteins that the team identified were associated with interleukin IL-6, a protein which causes inflammation, a known marker for severe symptoms. The researchers suggest it may be possible to alleviate some of these symptoms by using drugs that target these associated proteins.

Markus Ralser, paper author and group leader at the Crick and Charité, says: “The robust method we’ve used in this study is a valuable and powerful tool to predict disease progression and also find potential targets for treatments. Our approach could also be easily applied to other diseases, now and in the future, to understand more about their effects on the body.” Vadim Demichev, another lead author and scientist in the Molecular Biology of Metabolism Laboratory at the Crick adds, “While our technology platform was not developed specifically for COVID-19, it has proven highly useful to gain novel insights into this disease. We hope it will help the development of prognostic analytical tests for a broad range of conditions in the near future”.


Source: Francis Crick Institute

03.06.2020

Read all latest stories

Related articles

Photo

Multiple sclerosis

Epstein-Barr virus may be leading cause of MS

A connection between the Epstein-Barr virus and multiple sclerosis has long been suspected. A new study provides ‘compelling evidence of causality’.

Photo

Research

Quantum sensor to detect SARS-CoV-2 faster

Scientists at have designed a quantum sensor to detect SARS-CoV-2 faster, cheaper, and more accurate than the current gold-standard technique, PCR.

Photo

New study

Antibodies can neutralize omicron

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants.

Related products

Beckman Coulter – Early Sepsis Indicator

Blood Cell Counter

Beckman Coulter – Early Sepsis Indicator

Beckman Coulter Diagnostics
Beckman Coulter – SARS-CoV-2 Assays

Immunoassays

Beckman Coulter – SARS-CoV-2 Assays

Beckman Coulter Diagnostics
Lifotronic  SARS-CoV-2 Antibody Detection Kit

Immunoassays

Lifotronic SARS-CoV-2 Antibody Detection Kit

Lifotronic Technology Co., Ltd
Lifotronic – SARS-CoV-2 Antigen

Immunoassays

Lifotronic – SARS-CoV-2 Antigen

Lifotronic Technology Co., Ltd
Lifotronic – SARS-CoV-2 Nucleic Acid Detection Kit

Detection

Lifotronic – SARS-CoV-2 Nucleic Acid Detection Kit

Lifotronic Technology Co., Ltd
Subscribe to Newsletter